Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 25 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Cancer immunotherapy has undergone revolutionary progress in recent years, mainly due to the breakthrough response associated with immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway. Despite their promising success in the market, these are associated with few challenges which need to be overcome. Therefore, research studies related to immune checkpoint inhibitors from past few years have inclined to the identification of novel biomarkers which is a characteristic that can be measured as an indicator of normal or pathogenic biological processes or of responses to an exposure or intervention.
The biomarkers play increasingly prominent role in drug development and are used across all stages of drug development, ranging from enrichment, stratification, and patient selection to safety, efficacy, and performance assessment. Apart from this, biomarkers can be used in multiple setting including cancer diagnosis, treatment, and follow-up. This includes risk assessment, screening, differential diagnosis, determination of prognosis, response to treatment, disease status, and safety monitoring. In addition, biomarkers may help detect cancer recurrence or progression. These promising applications associated with the development of biomarkers have gathered interest from several pharmaceutical giants to invest in this segment. Currently, more than 500 clinical trials are ongoing in immune checkpoint inhibitor biomarker market, thus suggesting promising future of the market.
Pharmaceutical companies are also developing several Oncologic companion diagnostic tests (CDx) which are biomarker assays used to inform the management of patients by identifying treatment options that may be appropriate based on the unique drivers of their individual tumors. Over the past few years, FDA has approved a number of CDx across cancer types, including immunohistochemistry-based assays such as PD-L1 IHC 22C3 pharmDx for identifying individuals with non-small cell lung cancer (NSCLC) who may be candidates for pembrolizumab (Keytruda) and FoundationOne CDx a companion diagnostic for identifying tumors that are microsatellite instability–high and may benefit from pembrolizumab.
Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the immune checkpoint biomarkers market players focus on the partnership or collaboration strategy which permits them to maintain their brand name across the world. For instance, Promega Corporation has entered into collaboration with Merck to develop Promega’s microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) for use with Merck’s anti-PD-1 therapy, Keytruda.
As per our report findings, the global immune checkpoint biomarker market will surpass US$ 25 Billion by 2028 which is mainly due to rapid adoption of immune checkpoint inhibitors for the management of cancer. Furthermore, upsurge in the public-private funding for target research activities, increasing popularity of personalized medicine, increasing awareness regarding malignancies among patients and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period. On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities and lack of clarity regarding several basic elements including the utility of biomarker-based tests are expected to obstruct market growth.
Our report Immune checkpoint inhibitor biomarker market provides in-depth analysis on market size, share, recent development, and trends. The report also provides comprehensive analysis on the clinical trials related to biomarkers in various phases and across different indications. Aside from this, report also gives description of competitive landscape to help investors, key players, and new entrants gain a significant portion of the global market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com